First Direct-to-Consumer BRCA Test Authorized by FDA

The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.

Mar 6, 2018
Kerry Grens

ISTOCK, PHOTOVIDEOSTOCKThe Food and Drug Administration (FDA) has allowed the direct-to-consumer genetics company 23andMe to offer a test for mutations in the BRCA1 and BRCA2 genes, the agency announced today (March 6). The three mutations included in the screen increase the risk of breast and ovarian cancer, and are most common among people of Ashkenazi Jewish decent.

“Being the first and only direct-to-consumer genetics company to receive FDA authorization to test for cancer risk without a prescription is a major milestone for 23andMe and for the consumer,” Anne Wojcicki, 23andMe CEO and cofounder, says in a press release.

The FDA made a point to note that there are more than 1,000 cancer-related mutations in BRCA genes, and just about 2 percent of Ashkenazi Jewish women carry the three mutations in the test. They are rarely found outside this group. According to 23andMe, any of the variants increase a woman’s chance of breast cancer before age 70 by 45 percent to 85 percent.

“While the detection of a BRCA mutation on this test does indicate an increased risk, only a small percentage of Americans carry one of these three mutations and most BRCA mutations that increase an individual’s risk are not detected by this test,” Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, says in a press release.

“At a minimum, 23andMe should be clear with people about what their test is and isn’t and present the information in a fair and balanced way that the average person can understand,” Ron Rogers, a spokesman for Myraid Genetics, which developed the first BRCA tests, tells STAT News.

According to 23andMe, new and existing customers will have access to the results of the screen several weeks from now.

Correction (March 19): The headline was fixed to state that the FDA has authorized 23andMe to market its test. The agency did not approve the test. For more on the difference, see “Opinion: No, FDA Didn’t Really Approve 23andMe’s BRCA Test.”

November 2018

Intelligent Science

Wrapping our heads around human smarts


Sponsored Product Updates

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.